Miniatura

Fitxers

688464.pdf (713.41 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2019-02-01

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/164943

Induced Vitiligo due to Talimogene Laherparepvec Injection for Metastatic Melanoma Associated with Long-term Complete Response

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.2340/00015555-3061

Resum

Talimogene laherparepvec (T-VEC) (Imlygic, Amgen) is the first oncolytic virus approved for use in therapy for metastatic melanoma. T-VEC provides a treatment option for patients with limited metastatic disease. T-VEC is a genetically modified, live, attenuated herpes simplex virus type 1 designed to replicate in tumour cells and promote an enhanced anti-tumour response (1) T-VEC is administered by injection into cutaneous, subcutaneous or nodal lesions, which are visible and/or palpable and/ or visualized by ultrasonography (2). Other local management options have been used to control metastatic disease in stage IIIB, but almost all have shown only a local effect and rapid disease relapse (3, 4). With T-VEC, responses occurred in injected and uninjected lesions, including a greater than 50% decrease in size in 15% of uninjected visceral lesions. The appearance of vitiligo has been described as an adverse event after administration of immune checkpoint inhibitors (5, 6). It has been reported as a marker of activity of the drug and long-term results, inducing clinicians to use it as a predictor of drug response (7). A T-VEC phase II study has reported 85% adverse events, all of which were grade 1 or 2. The appearance of vitiligo has been described in 3 patients out of 50 (8), although no details regarding duration and appearance have been reported.

Matèries

Càncer de pell, Vitiligen, Melanoma

Matèries (anglès)

Skin cancer, Vitiligo, Melanoma

Citació

Col·leccions

Articles publicats en revistes (Medicina)

Citació

IGLESIAS, Pablo, RIBERO, Simone, BARREIRO CAPURRO, Alicia, PODLIPNIK, Sebastian, CARRERA ÁLVAREZ, Cristina, MALVEHY, J. (josep), PUIG I SARDÀ, Susana. Induced Vitiligo due to Talimogene Laherparepvec Injection for Metastatic Melanoma Associated with Long-term Complete Response. _Acta Dermato-Venereologica_. 2019. Vol. 99, núm. 2, pàgs. 232-233. [consulta: 25 de febrer de 2026]. ISSN: 0001-5555. [Disponible a: https://hdl.handle.net/2445/164943]

Exportar metadades

JSON - METS

Compartir registre